Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Omid Hamid, ASCO 2021: Nemvaleukin Alfa and the ARTISTRY-2 Trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 13th 2021

touchONCOLOGY joins Dr Omid Hamid (Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, Los Angeles, CA, USA) at ASCO 2021 to discuss nemvaleukin alfa and the ARTISTRY-2 trial.

The abstract ‘Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2’ (NCT03861793) (abstract number 2552) was presented at the 2021 ASCO Annual Meeting.

Abstract

Poster

Questions
1. Could you tell us a little about nemvaleukin alfa and its mechanism of action? (0:15-01:32)

2. What are the aims of the ARTISTRY clinical trial program, and what have we learned to date? (01:32-02:49)

3. Which tumour types were included in ARTISTRY-2? (02:49-04:09)

4. What were the efficacy and safety findings of ARTISTRY-2? (04:09-05:15)

5. What will be the next steps in the ARTISTRY clinical trial program? (05:15-07:26)

Disclosures: Consulting/Advisory Boards: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Roche Genentech, GSK, Immunocore, Idera, Incyte, Janssen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, Seattle, Genetics, Tempus, Zelluna. Speaker Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron. Contracted Research (For Institution): Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, CytomX, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck-Serono, NextCure, Novartis, Pfizer, Sanofi/Regeneron, Seattle Genetics, Torque, Zelluna.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Helen Fowler.

Filmed in coverage of the 2021 ASCO Annual Meeting.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup